Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-label, Non-controlled, Extension Study to Evaluate the Long-term Safety of TAK-771 in Japanese Patients With Primary Immunodeficiency Disease (PID)

NCT05513586 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT05513586
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05513586 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-label, Non-controlled, Extension Study to Evaluate the Long-term Safety of TAK-771 in Japanese Patients With Primary Immunodeficiency Disease (PID)
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
September 13, 2022
Completion date
October 30, 2025
Enrollment
15 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

primary immunodeficiency diseases (pid)